English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

This study evaluates dose rates at various distances and time intervals after  177 Lu-PSMA treatment and assesses caregivers’ effective doses. Dose rates were measured in 47 patients at 0.5 and 1 m up to 168 h post-injection. Initial dose rates were 34.6 ± 9 μSv (0.5 m) and 24.6 ± 5 μSv (1 m) at 5 min, peaking at 48.5 ± 15 and 31.6 ± 8 μSv at 1 h, then declining significantly over time. Caregivers’ effective doses ranged from 20 to 1170 μSv, remaining below international safety limits. This study demonstrates that patient dose rates at a distance of 1-m decline to below 30 μSv/h within 2–3 h post-injection and fall further to under 20 μSv/h after 6 h. Patients may be considered radiologically safe approximately four days post-procedure, depending on individual factors. While  177 Lu-PSMA is a safe and effective PRRT modality, strict safety measures are essential to minimize exposure risks.

Evaluation of external radiation exposure in patients treated with 177 Lu-PSMA and radiation safety assessment of the patient caregivers